AUS
NZ
UK
CA
USA
IND
Highlights
Tryptamine Therapeutics strengthens TRP-8803 program with two senior appointments
Australian-based team structure expected to enhance operational efficiency
Preparations underway for first-ever Binge Eating Disorder trial with Swinburne University
Tryptamine Therapeutics Ltd (ASX:TYP), listed on the All Ordinaries, has announced the expansion of its clinical team for its lead investigational treatment, TRP-8803. The company has appointed Professor Marcel Mozafari as senior formulation scientist and Professor David Castle as consultant medical officer. Both are based in Australia, which is expected to support a streamlined clinical program aligned with local regulatory and tax advantages.
The appointments arrive ahead of a world-first clinical trial for Binge Eating Disorder, being conducted in partnership with Swinburne University, and mark a key milestone in advancing the company’s investigational psychedelic-assisted treatment pipeline.
Professor Mozafari to Lead Formulation Science
Professor Marcel Mozafari steps into a full-time role at Tryptamine Therapeutics with extensive credentials in pharmaceutical nanotechnology. With decades of experience translating scientific research into drug development, his background includes leadership positions across R&D and formulation departments.
He brings a notable track record of scientific publications, with particular emphasis on bioavailability, controlled delivery systems, and commercial scaling of medical technologies. His technical oversight will focus on the development of TRP-8803, a proprietary intravenous psilocin formulation designed to improve upon limitations of oral psychedelic treatments.
Professor Castle to Strengthen Medical Oversight
Complementing the clinical leadership team, Professor David Castle joins in a permanent, part-time role as consultant medical officer. A respected psychiatrist and current Professor of Psychiatry at the University of Tasmania, Professor Castle is known for his prolific contributions to mental health research.
He has been an active member of the company’s Scientific Advisory Board and is involved in various studies using oral psilocybin therapies in Australia and Canada. His involvement in the trial design for TRP-8803 builds on his expertise in integrating psychedelic medicines into psychiatric treatment frameworks.
Clinical Program Milestones and Strategy
TRP-8803 is being developed as a next-generation psychedelic-assisted therapy targeting a range of unmet medical conditions. The company aims to differentiate the therapy through controlled intravenous delivery of psilocin, reducing variability in patient response and enabling shorter treatment sessions.
Earlier studies, including Phase 2a trials for fibromyalgia, Binge Eating Disorder, and irritable bowel syndrome, were conducted using TRP-8802, an oral synthetic psilocybin compound. Future trials are expected to transition to TRP-8803 for further development, with operational emphasis placed on safety, patient experience, and clinical efficacy.
The company continues to collaborate with leading research institutions, including the University of Florida, University of Michigan, Massachusetts General Hospital, and now Swinburne University, underscoring its commitment to clinical rigor and therapeutic innovation in the field of psychedelic-assisted treatments.
